Final answer:
VZIG is an effective measure to reduce the risk of developing chickenpox after exposure, but it does not guarantee complete protection. It can also help to reduce the risk of subclinical infection and fetal varicella syndrome in pregnant women. However, like any medication, there is a small risk of allergic reactions, including anaphylaxis, associated with VZIG administration.
Step-by-step explanation:
Effectiveness of VZIG is determined by several factors:
- % of individuals who will still have chickenpox: VZIG (varicella zoster immune globulin) is given to individuals who have been exposed to chickenpox but have not yet developed the infection. It provides passive immunity by giving them antibodies against the varicella zoster virus. While VZIG can reduce the severity of the infection, it does not guarantee complete protection. So, there is still a possibility that individuals who receive VZIG may still get chickenpox, but the risk is significantly lower compared to those who do not receive it.
- % of individuals having subclinical infection: Subclinical infection refers to an infection that doesn't cause noticeable symptoms. VZIG can reduce the likelihood of subclinical infection by providing passive immunity, but it doesn't eliminate the possibility entirely.
- % of babies with FVS: FVS (fetal varicella syndrome) is a condition that can occur when a pregnant woman contracts chickenpox. VZIG administration to pregnant women who have been exposed to chickenpox can reduce the risk of FVS in the baby.
- Anaphylactic risk: Like any medication, VZIG carries a risk of allergic reactions, including anaphylaxis. However, the risk is generally low, especially when VZIG is administered under appropriate medical supervision.